

Docket No.: 64868(47992)

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Sharon M. Wahl et al.

Application No.: 10/578,536

Filed: May 4, 2006

Art Unit: N/A

For: METHODS AND COMPOSITIONS FOR

THE INHIBITION OF HIV-1 REPLICATION

Examiner: Not Yet Assigned

Confirmation No.: 9065

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1.	[X] This replies to the Office Letter DATED	December 17, 2007

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

[X] A copy of the Office Letter is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

2.	١, _	Christi	ne C. O'Day	
			(type or print name of person signing below)	
	sta	ite the f	ollowing:	
			ITEMS BEING SUBMITTED	
3. Submitted herewith is/are			herewith is/are	
			(check each item as applicable)	
	A.	[X] "Se	equence Listing(s)" for the nucleotide and/or amino acid sequence(s) in application. Each "Sequence Listing" is assigned a separate identifier as rec in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823.	
	B.	[]	An amendment to the description and/or claims, wherein reference is made a sequence by use of the assigned identifier, as required in 37 C.F.R. § 1.821(d	
	C.	[X]	A copy of each "Sequence Listing" submitted for this application in comreadable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e1.824.	
	D.	[]	Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e computer readable copy(ies) from applicant's other application identified as follows:	
lde			outer readable form(s) of applicant's other application corresponds to the "Sequ f the application as follows:	ence
Computer Readable Form "Sequence I			eadable Form "Sequence Identi	ifier"
		r applic	ation) (this application)	tion)
		SEQ ID	NO:	

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new

application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. § 1.821(e).

- E. [X] A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).
 - [] Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. § 1.821(b).
- F. [X] Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.
 - [] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g).

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

- A. [X] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [X] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5.	Applicant is		
	[] a small entity. A statement:		
	[] is attached.		
	[] was already filed.		
	[X] other than a small entity.		

6.

EXTENSION OF TERM

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136 apply.

(complete (a) or (b) as applicable)

(a) [] Applicant petitions for an extension of time under 37 C.F.R. § 1.136 (fees: 37 C.F.R. § 1.17(a)(1)-(4)) for the total number of months checked below:

	Extension (months)	Fee for other than small entity	Fee for small entity
[] [] []	one month two months three months four months	\$110.00 \$380.00 \$870.00 \$1,360.00	\$ 55.00 \$ 190.00 \$ 435.00 \$ 680.00

Fee	\$

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

[] An extension for	months has already been secured, and the fee paid
therefor of \$	is deducted from the total fee due for the total months of
extension now re	equested.

Extension fee due with this request \$

OR

(b) [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

8. []] Attached is a check in the sum of \$				
[]	Charge Account No the sum A duplicate of this transmittal is attached.	of \$			
	FEE DEFIC	CIENCY			
NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary cover the additional time consumed in making up the original deficiency. If the maximum, six-month period is expired before the deficiency is noted and corrected, the application is held abandoned. In those instant where authorization to charge is included, processing delays are encountered in returning the papers to PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.					
10. [Χ	10. [X] If any additional extension and/or fee is required, charge Account No04-1105				
	SIGNATURE(s)				
DATE:	: <u>January 17, 2008</u>	Christine C. O'Day (Reg. 38,256) Attorney for Applicants EDWARDS ANGELL PALMER &DODGE LLP P.O. Box 55874 Boston, MA 02205			
	: (617) 239-0100 No. 38,256	 [] Inventor [] Assignee of complete interest [] Person authorized to sign on behalf of assignee [X] Practitioner of record [] Filed under Rule 34(a) [] Registration No. [] Other 			

BOS2_651643.1



Docket No.: 64868(47992)

(PATENT)

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Sharon M. Wahl et al.

Application No.: 10/578,536

Filed: May 4, 2006 Art Unit: N/A

For: METHODS AND COMPOSITIONS FOR

THE INHIBITION OF HIV-1 REPLICATION

Examiner: Not Yet Assigned

Confirmation No.: 9065

STATEMENT PURSUANT TO 37 CFR 1.821(f)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Submitted herewith for filing in connection with the above-referenced patent application is a paper copy of the Sequence Listing and a labeled, computer readable copy of the Sequence Listing.

I hereby state that I have reviewed the paper copy of the Sequence Listing, as required by 37 CFR 1.821(c), and have reviewed the computer readable form of the Sequence Listing, as required by 37 CFR 1.821(e), and that the content of the paper and computer readable copies for the above-referenced patent application are the same as required by 37 CFR 1.821(f).

By

Early favorable consideration of the patent application is respectfully solicited.

Dated: January 17, 2008

Respectfully submitted,

Christine C. O'Day

Registration No.: 38,256

uit Ch

Application No.: 10/578,536 2 Docket No.: 64868(47992)

EDWARDS ANGELL PALMER & DODGE LLP P.O. Box 55874 Boston, Massachusetts 02205 (617) 517-5558 Attorneys/Agents For Applicant

BOS2_651655.1